A realistic, evidence-based plan for lowering — not eliminating — your risk of a second squamous cell carcinoma
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
If you've already had one squamous cell carcinoma (SCC), you're at meaningfully higher risk of developing another — both because the sun damage that caused the first one is still present in the surrounding skin, and because whatever made you susceptible (skin type, cumulative UV exposure, immune status) hasn't changed. Studies consistently find that people with one keratinocyte cancer have a substantially higher chance of a second one within the following years compared to the general population.
That's the reality this guide starts from: prevention here isn't about avoiding a first diagnosis, it's about reducing the odds of a repeat one. None of the steps below bring your risk to zero, which is exactly why they're paired with ongoing surveillance rather than treated as a one-time fix.
Sun protection matters more, not less, after an SCC diagnosis. The routine that actually reduces risk combines several habits rather than relying on any single product:
Skin that has developed one SCC has usually absorbed years of UV damage across a wider area than the tumor itself — a concept dermatologists call "field cancerization." That damaged field often contains actinic keratoses (AKs), precancerous spots that share the same UV-driven origin as SCC, and treating them proactively — rather than only reacting to new individual lesions — measurably reduces the future burden of skin cancer in that area.
Field-directed treatments (topical 5-fluorouracil, imiquimod, photodynamic therapy, or diclofenac gel, depending on your dermatologist's recommendation) address visible AKs and the subclinical damage around them at the same time. If you have multiple AKs, our actinic keratosis treatment options guide and guide to field therapy for multiple AKs cover how these approaches work and how to choose between them.
The ONTRAC trial, a phase 3 randomized controlled study, tested oral nicotinamide 500 mg twice daily in 386 people with a history of at least two nonmelanoma skin cancers. Over 12 months, the nicotinamide group had about 23% fewer new nonmelanoma skin cancers than the placebo group. It's inexpensive, available without a prescription, and well tolerated, which is why many dermatologists now recommend it for patients with a strong history of repeat keratinocyte cancers — though its benefit requires ongoing use and is modest, not a replacement for sun protection.
For patients at the highest risk of repeated SCC — most notably organ transplant recipients, whose long-term immunosuppression dramatically raises SCC risk — oral retinoids such as acitretin have the strongest evidence of any chemoprevention option. A study of low-dose acitretin in solid-organ transplant recipients found a significant reduction in new keratinocyte carcinomas during treatment. Retinoids require specialist supervision because of side effects like dry skin, elevated blood lipids, and the need for monitoring, so this is a decision made together with a dermatologist experienced in transplant dermatology.
A weakened immune system — from organ transplant medication, certain autoimmune drugs, or conditions like chronic lymphocytic leukemia — is one of the strongest risk factors for developing multiple or aggressive SCCs. If you're on long-term immunosuppression, this is worth an active conversation between your dermatologist and the specialist managing that medication (your transplant team or rheumatologist), since in some cases the immunosuppressive regimen itself can be adjusted to lower skin cancer risk while still protecting the organ or condition it's treating. This is never a decision to make on your own — stopping or reducing immunosuppression without medical guidance can risk organ rejection or a serious disease flare, and any change has to be coordinated and monitored by the team who prescribed it.
Every step above reduces risk — none of them eliminates it. That's the reason scheduled dermatology follow-up remains essential even for someone doing everything right on the prevention side. Regular professional skin exams catch new or recurrent SCC while it's still small and straightforward to treat, and monthly self-checks between visits catch changes sooner than an annual appointment alone would.
Our SCC follow-up care guide covers how often you should be seen based on your risk level, and our guide to self skin checks walks through how to do a thorough exam at home and what changes should prompt a call to your dermatologist sooner than your next scheduled visit.
After one SCC, prevention is a layered effort: rigorous daily sun protection, proactively treating the actinic keratoses and field damage that share the same cause, and — for the right patients — chemoprevention with nicotinamide or, for very high-risk cases like transplant recipients, a supervised retinoid.
None of this guarantees you won't develop another SCC, which is exactly why it's paired with regular dermatology follow-up and consistent self-checks. Together, prevention and surveillance are what actually keep a second SCC small, early, and easy to treat if it does occur.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist before starting any chemoprevention medication or changing an immunosuppressive regimen.
Chat with our AI guide for personalized information about preventing another SCC
Chat with the Navigator